moneyheap
SMMT · Analysis updated Nov 11, 2026, 4:46 PM ET
Why is Summit Therapeutics Inc. (SMMT) stock moving?
SMMT traded near $16.64 on Nov 11, down about 6.7% from the $17.83 close, with volume of 3.8M shares. The drop came after a Nov 9 rally to $17.84 on 7.2M shares. The stock is positioned ahead of the Nov 14 FDA decision on ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy. The Phase 3 trial met its progression-free survival goal. Its initial overall survival analysis was not statistically significant, though updated data showed a 24% reduction in the risk of death (hazard ratio 0.76). This leaves the outcome uncertain. Supports for the stock include the $2B AstraZeneca equity investment, new combination collaborations, and Moderate Buy analyst consensus (10 buys, 1 strong buy, 7 holds, 1 sell). Risks include the Q2 net loss of $215.7M, a $380M at-the-market program, a new prospectus supplement for share issuance, and an increase in authorized shares, which point to possible dilution. The stock is well below its 12-month high of $29.23. The outcome is binary and near-term moves will likely be driven by the decision.
News behind the analysis
- FDA Decision Watch: Summit's Lung Cancer Drug, Cytokinetics' Heart Therapy And Teva's Igalmi In Spotlight This WeekThe FDA decision on ivonescimab follows a Phase 3 trial that missed statistical significance on overall survival in its primary analysis. Updated results showed a 24% reduction in the estimated risk of death.
- Nasdaq 100 Jumps 2.8% as CoreWeave, Nvidia Climb: Stock Market TodaySMMT fell 4.94% ahead of the FDA decision on ivonescimab expected this week, and was among the Russell 1000's top losers.
- Weekly Recap: Ivonescimab FDA action date and AstraZeneca $2B investmentThe FDA action date is Nov 14. The HARMONi overall survival hazard ratio was 0.76, and HARMONi-3 data are due from Q4 2026.
- Summit Therapeutics PLC (SMMT) - What Are Researchers Saying About This Stock?Analyst consensus is Moderate Buy across 19 ratings. Barclays has an equal weight rating with a $20 target.
- SMMT: Summit Therapeutics Inc. - Stock Price, Quote and News - CNBCSummit filed a prospectus supplement for a share issuance, and stockholders approved an increase in authorized shares. Barclays stayed at Hold on Nov 4.
- FDA Accepts Ivonescimab Application for EGFR Lung CancerThe FDA accepted the BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy. The agency's review includes mid-cycle and wrap-up meetings.
- Summit Therapeutics (SMMT) Stock Price & OverviewThe page covers the AstraZeneca $2B equity investment and the Datroway combination collaboration. It also notes proxy filings in October.
- Summit TherapeuticsApproval would be Summit's first marketed product and the first Western approval of ivonescimab. The company has no approved product yet.
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics is a clinical-stage cancer drug developer built around one experimental medicine, ivonescimab. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF, and Summit licensed it from China's Akeso. Summit holds the rights in North America, South America, Europe, the Middle East, Africa and Japan, and the FDA is due to decide on its first US approval, in a type of EGFR-mutated lung cancer, by November 14, 2026.
How it makes money
Summit has no approved products yet, so it has essentially no product sales. It pays for its trials with cash raised from investors and partners. It started 2026 with roughly $710 million in cash, and in September 2026 AstraZeneca agreed to invest about $2 billion as part of a deal to test ivonescimab alongside AstraZeneca's cancer drugs. If ivonescimab is approved, future revenue would come from selling it in Summit's licensed regions.
What usually moves SMMT
- FDA decision on ivonescimab (PDUFA date November 14, 2026)
- Phase III trial readouts, especially overall survival data
- Data from partner Akeso's trials in China
- Partnerships and funding, such as the AstraZeneca deal
- Competing PD-1/VEGF bispecific drugs